Intralymphatic allergen-specific immunotherapy: An effective and safe alternative treatment route for pollen-induced allergic rhinitis

Hylander, Terese; Latif, Leith; Petersson-Westin, Ulla; Cardell, Lars Olaf

doi:10.1016/j.jaci.2012.10.056

Cited by 126 publications

(183 citation statements)

References 98 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…immunotherapy can induce changes similar to oral immunotherapy with fewer systemic side effects (ClinicalTrials.gov identifier: NCT01904604). Other routes of therapy, including intradermal and intralymphatic immunotherapy, are also showing promising results in preclinical and clinical trials of other allergens (97)(98)(99)(100)(101).…”

Section: Pathophysiology Of Food Allergymentioning

confidence: 99%

Emerging therapies for food allergy

Keet¹,

Wood²

2014

J. Clin. Invest.

View full text Add to dashboard Cite

Food allergy is a common condition for which there are currently no approved treatments except avoidance of the allergenic food and treatment of accidental reactions. There are several potential treatments that are under active investigation in animal and human studies, but it is not yet clear what the best approach may be. Here, we review approaches that are currently in clinical trials, including oral, sublingual, and epicutaneous immunotherapy, immunotherapy combined with anti-IgE, and Chinese herbal medicine as well as approaches that are in preclinical or early clinical investigation, including modified protein immunotherapy, adjuvants, DNA vaccines, and helminth administration. We discuss the importance of fully exploring the risks and benefits of any treatment before it is taken to general clinical practice and the need for clarity about the goals of treatment.

show abstract

Section: Pathophysiology Of Food Allergymentioning

confidence: 99%

Emerging therapies for food allergy

Keet¹,

Wood²

2014

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…Both novel strategies showed similar efficacy in the treatment of grass pollen allergy. Results gathered from recent studies have shown less demand on numbers of shots as well as on less total dose of allergen [77,78].…”

Section: Future Of Subcutaneous Allergen Immunotherapymentioning

confidence: 99%

Present and Future of Subcutaneous Aero-Allergen Immunotherapy

Lukan¹

2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

The present review summarizes the literature-acquired knowledge as well as author's own experience in conducting aero-allergen immunotherapy, particularly in subcutaneous route of administration (SCIT) of all modalities of respiratory allergy disease from allergic rhinosinusitis, bronchial asthma to united airway disease. Because of the better adherence resulting in appropriate efficacy in connection with satisfactory safety, the author favours conventional schedules of subcutaneous route of therapeutic intervention. Given the lack of specific biomarker in monitoring treatment course, the main control mechanism of efficacy is the evaluation of quality of life using simple evaluation scale as visual analogue scale or standardized respiratory allergy questionnaires. The future of allergen immunotherapy should be focused on new routes of allergen administration (e.g. oral, epicutaneous, intradermal, intralymphatic) and on the searching potential biomarkers which could be objectively measured and easily accessible from body fluids (blood, nasal secretion, sputum). The combination of estimated biomarkers obtained from biological samples in conjunction with evaluation of quality of life could lead to the generation of the overall satisfactory monitoring protocol.

show abstract

“…Allergen-SIT vaccines are administered directly into inguinal lymph nodes with the aim of delivering high amounts of allergens into secondary lymphatic organs [22,23]. Significantly fewer systemic allergic reactions were observed, more patients were able to reach the target maintenance immunotherapy dose [29,30] strategy that has been tested is the fusion of FcgRIIb to allergens to down-regulate downstream allergenspecific immune responses.…”

Section: Key Pointsmentioning

confidence: 99%

“…The demonstrated advantage of these approaches involves fewer doses, that is, patients' visits at the office and lower total dose of allergen required to achieve clinical efficacy [22][23][24]. However, both indirect efficacy comparisons show similar efficacy to SCIT in the treatment of grass pollen allergy.…”

Section: Routes Of Vaccine Administrationmentioning

confidence: 99%

Novel immunotherapy vaccine development

Jutel

Akdiş

2014

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

PURPOSE OF REVIEW: Allergen-specific immunotherapy is the only curative treatment for allergic diseases. In spite of the great progress in both vaccine development and the methods of allergen immunotherapy (AIT) in recent years, several key problems related to limited efficacy, side-effects, low patient adherence and the relatively high costs due to the long duration (3-5 years) remain to be solved. The current approaches aiming at optimization of AIT are reviewed, including both conceptual studies in experimental models and proof-of-concept -as well as large, multicenter clinical studies. RECENT FINDINGS: The most promising approaches to improve efficacy and safety of vaccine-based AIT include bypassing IgE binding and targeting allergen-specific T cells using hypoallergenic recombinant allergen derivatives and immunogenic peptides, the use of new adjuvants and stimulators of the innate immune response, the fusion of allergens to immune modifiers and peptide carrier proteins and new routes of vaccine administration. SUMMARY: The cloning of allergen proteins and genetic engineering enabled the production of vaccines that have well defined molecular, immunologic and biologic characteristics as well as modified molecular structure. These new compounds along with new immunization protocols can bring us closer to the ultimate goal of AIT, that is, complete cure of a large number of allergic patients. Purpose of reviewAllergen-specific immunotherapy is the only curative treatment for allergic diseases. In spite of the great progress in both vaccine development and the methods of allergen immunotherapy (AIT) in recent years, several key problems related to limited efficacy, side-effects, low patient adherence and the relatively high costs due to the long duration (3-5 years) remain to be solved. The current approaches aiming at optimization of AIT are reviewed, including both conceptual studies in experimental models and proof-ofconcept -as well as large, multicenter clinical studies. Recent findingsThe most promising approaches to improve efficacy and safety of vaccine-based AIT include bypassing IgE binding and targeting allergen-specific T cells using hypoallergenic recombinant allergen derivatives and immunogenic peptides, the use of new adjuvants and stimulators of the innate immune response, the fusion of allergens to immune modifiers and peptide carrier proteins and new routes of vaccine administration. SummaryThe cloning of allergen proteins and genetic engineering enabled the production of vaccines that have well defined molecular, immunologic and biologic characteristics as well as modified molecular structure. These new compounds along with new immunization protocols can bring us closer to the ultimate goal of AIT, that is, complete cure of a large number of allergic patients.

show abstract

Intralymphatic allergen-specific immunotherapy: An effective and safe alternative treatment route for pollen-induced allergic rhinitis

Cited by 126 publications

References 98 publications

Emerging therapies for food allergy

Emerging therapies for food allergy

Present and Future of Subcutaneous Aero-Allergen Immunotherapy

Novel immunotherapy vaccine development

Contact Info

Product

Resources

About